BioSpace News Archive

EVOQ Therapeutics today announced the advancement of their ongoing license and collaboration agreement with Amgen for the discovery and development of novel therapeutics including the receipt of a milestone payment and expansion of the scope of collaboration to include a total of three indications in autoimmune disorders.

Asep Medical Holdings Inc. is pleased to announce that it is holding an online webinar on January 24, 2023, at 1:00 pm EST to provide essential and exciting updates on the company’s global market developments, scientific advances and investment-related milestones.

SciSparc Ltd. today announced it has been granted an approval by the Soroka University Medical Center (“Soroka Medical Center”) to conduct its clinical study for SCI-210 in patients suffering from autism spectrum disorder (“ASD”).

Capsida Biotherapeutics Inc. (“Capsida”) today announced the appointment of Julie Hakim to the role of chief financial officer (CFO).

SAB Biotherapeutics announced today that the company has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research.

Hinge Bio, Inc. today announced the expansion of its senior management team, which is expected to drive the Company’s GEM-DIMER™ programs, with an initial focus in oncology, to clinical development.

Pasithea Therapeutics Corp. today announced its contract with WuXi STA, a subsidiary of WuXi AppTec, to manufacture the active pharmaceutical ingredient (“API”) for Pasithea’s macrocyclic, next-generation MEK Inhibitor, PAS-004 (formerly CIP-137401).

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) is pleased to announce that the PsiGAD1 clinical trial, designed to assess Incannex’s psilocybin-assisted psychotherapy for the treatment of generalised anxiety disorder (“GAD”), has achieved its interim milestone of 29 patients completing primary endpoint assessments.

Lunit (KRX:328130.KQ) today announced that it will deliver two poster presentations at the upcoming 2023 ASCO Gastrointestinal Cancers Symposium (ASCO GI), to be held in San Francisco, CA, and online from Jan. 19 – 21.

NeuroBo Pharmaceuticals, Inc. today announced that it has appointed Joseph Hooker as Interim Chief Executive Officer and President.